A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

(Daunorubicin and Cytarabine) Liposome (VYXEOS)

(Daunorubicin and Cytarabine) Liposome interferes with DNA synthesis to slow cancer cell or viral replication.

First FDA approval2017-08-03
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is (Daunorubicin and Cytarabine) Liposome used for?

(Daunorubicin and Cytarabine) Liposome interferes with DNA synthesis to slow cancer cell or viral replication.

Is there a generic for (Daunorubicin and Cytarabine) Liposome?

No. (Daunorubicin and Cytarabine) Liposome is brand-only with no generic equivalents currently in market.

How much does my plan pay for (Daunorubicin and Cytarabine) Liposome?

NADAC pricing data not currently available for this drug.

Is (Daunorubicin and Cytarabine) Liposome on the FDA shortage list?

No. (Daunorubicin and Cytarabine) Liposome is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Nucleoside Metabolic Inhibitor6 alternatives in D1
01
Azacitidine
Brand: ONUREG
Lowest NADAC
13Generic mfrs
$138.5MCY24 Part D spend
Compare →
02
Azacitidine For
Brand: AZACITIDINE
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Capecitabine
Brand: XELODA
$0.396Lowest NADAC
11Generic mfrs
$74,309CY24 Part D spend
Compare →
04
Cedazuridine and Decitabine
Brand: INQOVI
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Clofarabine
Nucleoside Metabolic Inhibitor
Lowest NADAC
8Generic mfrs
CY24 Part D spend
Compare →
06
Cytarabine
Nucleoside Metabolic Inhibitor
Lowest NADAC
7Generic mfrs
$557CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.